These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3197751)

  • 81. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome.
    Rustin MH; Grimes SM; Kovacs IB; Cooke ED; Bowcock SA; Sowemimo-Coker SO; Turner P; Kirby JD
    Eur J Clin Pharmacol; 1984; 27(1):61-5. PubMed ID: 6386490
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.
    Smith CD; McKendry RJ
    Lancet; 1982 Dec; 2(8311):1299-301. PubMed ID: 6128596
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Double-blind, randomised, placebo controlled low level laser therapy study in patients with primary Raynaud's phenomenon.
    Hirschl M; Katzenschlager R; Ammer K; Melnizky P; Rathkolb O; Kundi M
    Vasa; 2002 May; 31(2):91-4. PubMed ID: 12099151
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists.
    Gleerup G; Persson B; Hedner T; Winther K
    Eur J Clin Pharmacol; 1993; 44(2):121-5. PubMed ID: 8453957
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
    Amstein R; Fetkovska N; Pletscher A; Bühler FR
    J Hypertens; 1989 Apr; 7(4):255-60. PubMed ID: 2723427
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cold hands after exposure to arsenic or vibrating tools: effects of ketanserin on finger blood pressure and skin temperature.
    Lagerkvist BE; Linderholm H
    Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):327-32. PubMed ID: 2943135
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Mechanism of action of ketanserin in hypertension and vasospastic disease.
    Wenting GJ; Brouwer RM; vd Meiracker AJ; Man in't Veld AJ; Schalekamp MA
    Acta Cardiol; 1987; 42(5):339-54. PubMed ID: 2827406
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon.
    Kallenberg CG; Vellenga E; Wouda AA; The TH
    J Rheumatol; 1982; 9(6):878-84. PubMed ID: 7161779
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Sublingual and oral isoxsuprine in patients with Raynaud's phenomenon.
    Wesseling H; den Heeten A; Wouda AA
    Eur J Clin Pharmacol; 1981; 20(5):329-33. PubMed ID: 7026260
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The efficacy of thymoxamine in primary Raynaud's phenomenon.
    Grigg MJ; Nicolaides AN; Papadakis K; Wolfe JH
    Eur J Vasc Surg; 1989 Aug; 3(4):309-13. PubMed ID: 2527760
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Raynaud's phenomenon.
    Belch JJ
    Curr Opin Rheumatol; 1989 Dec; 1(4):490-8. PubMed ID: 2702051
    [No Abstract]   [Full Text] [Related]  

  • 93. The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.
    De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
    Agents Actions; 1985 Jul; 16(5):313-7. PubMed ID: 2931964
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The treatment of Raynaud's phenomenon.
    Seibold JR; Allegar NE
    Clin Dermatol; 1994; 12(2):317-21. PubMed ID: 8076271
    [No Abstract]   [Full Text] [Related]  

  • 95. Amlodipine in the treatment of Raynaud's phenomenon.
    La Civita L; Pitaro N; Rossi M; Gambini I; Giuggioli D; Cini G; Ferri C
    Br J Rheumatol; 1993 Jun; 32(6):524-5. PubMed ID: 8508292
    [No Abstract]   [Full Text] [Related]  

  • 96. Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia.
    Rey J; Cretel E; Jean R; Pastor MJ; Durand JM
    Rheumatology (Oxford); 2003 Apr; 42(4):601-2. PubMed ID: 12649412
    [No Abstract]   [Full Text] [Related]  

  • 97. Adrenoceptors on blood cells from patients with primary Raynaud's phenomenon.
    Jeremy JY; Gill J; Barradas MA; Mikhailidis DP
    Clin Sci (Lond); 1991 Sep; 81(3):447. PubMed ID: 1655348
    [No Abstract]   [Full Text] [Related]  

  • 98. Ketanserin versus placebo in carcinoid syndrome. A clinical controlled trial.
    Gustafsen J; Lendorf A; Raskov H; Boesby S
    Scand J Gastroenterol; 1986 Sep; 21(7):816-8. PubMed ID: 3535008
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Raynaud's phenomenon and serotonin reuptake inhibitors.
    Garcia-Porrua C; Margarinos CC; Gonzalez-Gay MA
    J Rheumatol; 2004 Oct; 31(10):2090; author reply 2090-1. PubMed ID: 15468384
    [No Abstract]   [Full Text] [Related]  

  • 100. Successful treatment of Raynaud's phenomenon with limaprost, an oral prostaglandin E1 analogue.
    Tsukamoto H; Nagasawa K
    Br J Rheumatol; 1991 Aug; 30(4):317. PubMed ID: 1863837
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.